In 2020 the BIEL CEO stated the goal of selling the company

New Post Public Reply Private Reply Replies (1) Message Board
Bielionaire
158
In 2020 the BIEL CEO stated the goal of selling the company and retiring within four years.
Here is how that can actually happen — starting right now. 

For four years, that statement has just been a line in an old interview.

Today, for the first time, the conditions exist to make it real.

And the key is simple:

Ken Mayer + Electrome + BIEL’s public‑company status = a clean, executable path to a sale.

1. Mayer’s exit from Electrome unlocks the move that wasn’t possible before
When Mayer reportedly declined the BIEL CEO job (stated in his first investor call a few weeks ago according to Gofer/Gopher) earlier this year, it wasn’t because he didn’t want it.

It was because he couldn’t take it.

He was CEO of Electrome.
Electrome depends on BIEL hardware.
He couldn’t run both sides of the same ecosystem.

Now?

He’s out.

The conflict barrier is gone.

His reputation is intact.

Electrome is shifting to a founder‑led, science‑first model.

This is the first moment where a Mayer = BIEL CEO transition is structurally possible.

2. Mayer’s relationship with Electrome is EXACTLY what enables a sale

Mayer isn’t just “familiar” with BIEL.

He built Electrome’s entire platform on top of BIEL’s hardware.
He validated it.
He integrated it.
He commercialized it.
He knows the tech better than anyone outside BIEL itself.

Now imagine this structure:

Electrome (private) = AI, software, clinical, deep‑tech
BIEL (public) = hardware, manufacturing, distribution, capital markets
Put Mayer at the helm of the public entity and suddenly:

The ecosystem becomes vertically aligned

The valuation becomes scalable

The merger path becomes clean

The exit becomes realistic

This is how real biotech platforms are built before acquisition.

This is how you get to a sale.

3. BIEL being publicly traded is the weapon that makes the exit possible
Electrome is private.
BIEL is public.

If Mayer becomes CEO of BIEL, the public entity becomes:

A capital‑markets engine
for manufacturing scale, distribution, and M&A.

A liquidity pathway
for Electrome investors in a future merger.

A valuation amplifier
because public markets price growth, not just revenue.

A clean acquisition target
because acquirers prefer public entities with transparent cap tables.

This is EXACTLY how you structure a company for a sale.

4. The CEO compensation package that makes Mayer say yes — WITHOUT diluting shareholders
Here is the updated, Musk‑style, performance‑only package:

100M shares for every $0.01 PPS increase, from $0.01 to $0.10
Total potential: 1,000,000,000 shares (1B)
Total dilution today: ZERO
Total cost today: ZERO

He only gets paid if he builds a billion‑dollar company.

How to make it non‑dilutive:
A) Insider Convertible Notes = Reallocation Pool
Insiders give up a tiny percentage of their convertibles.
They still profit massively because PPS appreciation multiplies the value of their remaining notes.

B) Performance‑Triggered Warrants
Not exercisable today.
Not dilutive today.
Only unlock at PPS milestones.
Cash‑exercise only = brings capital into BIEL.

C) Treasury Shares from a Buyback
If BIEL buys back even a small block, those shares can be held in reserve and transferred to Mayer only when milestones are hit.

5. How this leads directly to a sale
Here’s the exact sequence:

Step 1 — Mayer becomes CEO of BIEL
Commercial operator takes over the public entity.

Step 2 — Electrome + BIEL operate as a synchronized ecosystem
Hardware + AI = unified therapeutic platform.

Step 3 — PPS milestones are hit
VA expansion
CMS channels
3,700‑pharmacy rollout
AI‑driven outcomes data
Institutional visibility

Step 4 — Market cap expands
This is where the Musk‑style package works:
Mayer only gets paid if the valuation explodes.

Step 5 — Ecosystem becomes merger‑ready
Electrome investors gain liquidity.
BIEL shareholders gain scale.
The combined entity becomes uplist‑ready.

Step 6 — Strategic acquirers enter
Med‑tech, AI‑health, or digital therapeutics companies look for:

Proven hardware

Proven AI

Proven outcomes

Public‑company transparency

Scalable margins

This is EXACTLY what they buy.

Step 7 — The 2020 retirement/sale goal becomes real

SUMMARY 
In 2020 the BIEL CEO stated the goal of selling the company and retiring within four years.
Here is how that can finally happen.

Ken Mayer is now free to take the CEO role at BIEL.
Electrome is shifting to science.
BIEL is shifting to commercialization.
The conflict barrier is gone.
The timing is perfect.

Mayer’s relationship with Electrome creates a clean path to:

A synchronized hardware + AI ecosystem

A future merger

A scalable valuation

A real acquisition target

A CEO transition that aligns with the 2020 retirement plan

And the compensation package is simple:

100M shares for every $0.01 PPS increase up to $0.10 (1B total).
Zero dilution today.
Zero cost today.

This is how you build a billion‑dollar bioelectronic medicine platform.
This is how you structure a company for a sale.
This is how the 2020 retirement plan becomes reality.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Xiong'an New Area: People's Priorities Reshape Living Spaces

Updated Category News Views 278

Building a City for the People This here is about prioritizing people over skylines. Xiong'an New Area in Hebei Province is shaping up to be more than just a place on the map; it's an experiment in redefining urban living. Skyscrapers and traffic jams? Not on this menu. Instead, nature paves a graceful dance floor between mid-rise residences. Forget your bustling city...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 81

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 69

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 64

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 98

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 99

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 276

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 139

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Gene Therapy Brings Hope to Young Patients

Updated Category News Views 279

Transformative Journey of Gene Therapy for AADC Deficiency Laughter and joy filled the sunny lobby of a research clinic, where a spirited little boy named Sriansh Ojha played happily with his sister, marking a dramatic contrast to his early life struggles. This remarkable transformation is largely due to gene therapy, a groundbreaking treatment that has changed the...

Continue Reading
Damon Inc. Unveils $30 Million Equity Offering for Mobility Innovation

Updated Category News Views 224

Introduction to Damon's Innovative Strategy Damon Inc. has recently announced a substantial $30 million Regulation A+ equity offering, which is set to enhance its impressive lineup of personal mobility products. The company, renowned for its electric motorcycles, aims to leverage the proceeds not only to fuel innovation in its products but also to fortify its...

Continue Reading
Cindy Eckert: Shaping the Future of Women's Health Together

Updated Category News Views 375

Cindy Eckert's Impact on Women's Health Innovation Cindy Eckert, the remarkable Founder and CEO of Sprout Pharmaceuticals, has been announced as the keynote speaker for the highly anticipated Women's Health Summit at Harvard Business School. This significant event, scheduled for 2025, aims to unite leaders, investors, and innovators dedicated to transforming women's...

Continue Reading
VoiceBrain and Diga-Talk Forge Partnership to Enhance Communications

Updated Category News Views 270

VoiceBrain and Diga-Talk Solutions Collaborate for Innovation In a groundbreaking partnership, VoiceBrain, renowned for its AI voice analytics, has teamed up with Diga-Talk Solutions, specialists in Push-to-Talk (PTT) over cellular technology. This exciting collaboration was unveiled during a prominent industry event, aiming to revolutionize real-time communication across...

Continue Reading
AstaReal's Research Reveals Astaxanthin Benefits for Kids' Eyes

Updated Category News Views 234

AstaReal's Groundbreaking Research on Astaxanthin AstaReal, Inc. has made a significant advancement in understanding children's eye health with its innovative research on astaxanthin. This powerful antioxidant, derived from the microalgae Haematococcus pluvialis, has been recognized globally for its benefits in enhancing visual performance, particularly in adults....

Continue Reading